Loading
A phase 2/3 trial of Cisplatin in head and neck squamous cell carcinoma, run by Privo Technologies, now recruiting.
A Study Evaluating the Safety and Efficacy of PRV111, PRV211, and PRV131 in Subjects With Oral and Lung Cancers is a phase 2/3 interventional study registered as NCT05893888 by Privo Technologies, with 40 participants planned, started 2024-11-07 and due to reach its primary completion in 2026-10. Interventions recorded: PRV211 (Intraoperative Cisplatin System), PRV111 (Cisplatin Transmucosal System) and PRV131 (Cisplatin Intratumoral Injectable).
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Platinum agents, Cisplatin, Head and neck squamous cell carcinoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Oral cavity cancer (mouth and tongue), Platinum agents, Cisplatin, Head and neck squamous cell carcinoma and the tag pipeline.
Shares Platinum agents, Cisplatin, Cytotoxic chemotherapy and the tag pipeline.
Shares Platinum agents, Cisplatin, Cytotoxic chemotherapy and the tag pipeline.
Shares Platinum agents, Cisplatin, Cytotoxic chemotherapy and the tag pipeline.
Shares Platinum agents, Cisplatin, Cytotoxic chemotherapy and the tag pipeline.
Shares Oral cavity cancer (mouth and tongue), Head and neck squamous cell carcinoma and the tag pipeline.
Shares Platinum agents, Cisplatin, Head and neck squamous cell carcinoma, Cytotoxic chemotherapy and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/